Defactinib
- Generic Name
- Defactinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21F3N8O3S
- CAS Number
- 1073154-85-4
- Unique Ingredient Identifier
- 53O87HA2QU
- Background
Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.
- Associated Conditions
- -
- Associated Therapies
- -
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT06194929
- Locations
- ๐บ๐ธ
University of Iowa, Iowa City, Iowa, United States
๐บ๐ธHuntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- ๐ณ๐ฟ
Auckland City Hospital, Auckland, New Zealand
๐บ๐ธHonorHealth, Phoenix, Arizona, United States
๐บ๐ธUniversity of Arkansas, Little Rock, Arkansas, United States
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06007924
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.